Merck & Co Inc
PAR:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
PAR:MRK
Watchlist
Price: 100.7242 EUR -0.67% Market Closed
Market Cap: €256.9B

Net Margin

29.6%
Current
Improving
by 11.7%
vs 3-y average of 17.9%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
29.6%
=
Net Income
$19B
/
Revenue
$64.2B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
29.6%
=
Net Income
€19B
/
Revenue
$64.2B

Peer Comparison

Country Company Market Cap Net
Margin
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
992.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
541.8B USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
278.2B CHF
Loading...
CH
Novartis AG
SIX:NOVN
223.2B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Pfizer Inc
NYSE:PFE
151B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
FR
Sanofi SA
PAR:SAN
97.1B EUR
Loading...

Market Distribution

Higher than 92% of companies in the United States of America
Percentile
92st
Based on 15 072 companies
92st percentile
29.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Merck & Co Inc
Glance View

Nestled in the heart of the pharmaceutical industry, Merck & Co., Inc. stands as a titan of innovation and healthcare. Established in 1891, the company has grown and evolved, driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. At the core of Merck’s operations is its commitment to research and development (R&D), which serves as the lifeblood of its product pipeline. With billions poured annually into R&D, Merck seeks to uncover new medical breakthroughs that address unmet medical needs across diverse therapeutic areas, such as oncology, vaccines, infectious diseases, and diabetes. This relentless pursuit of scientific advancement is not only a testament to Merck’s commitment to health but also a critical factor in maintaining its competitive edge in a crowded market. Merck's business model is elegantly straightforward yet highly structured. Primarily, the company's revenue streams are powered by the sales of prescription medications and vaccines that emerge from their exhaustive research efforts. Products like Keytruda, a cancer immunotherapy, and Gardasil, a vaccine for human papillomavirus, are standout performers, championing Merck's ability to penetrate high-value markets and secure regulatory approvals across the globe. Beyond the development and sale of pharmaceuticals, Merck generates additional revenue through collaborations and partnerships with other companies, leveraging co-development and marketing agreements to extend its reach. Underpinning Merck's financial model is its rigorous approach to cost management and strategic acquisitions, which bolster its robust product line-up and keep the engines of growth humming. This strategic orchestration ensures that while Merck fulfills its corporate mission, it also aligns with shareholder interests, reflecting a harmonious balance that has supported its storied legacy.

MRK Intrinsic Value
113.1035 EUR
Undervaluation 11%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
29.6%
=
Net Income
$19B
/
Revenue
$64.2B
What is Merck & Co Inc's current Net Margin?

The current Net Margin for Merck & Co Inc is 29.6%, which is above its 3-year median of 17.9%.

How has Net Margin changed over time?

Over the last 3 years, Merck & Co Inc’s Net Margin has increased from 25.9% to 29.6%. During this period, it reached a low of 0.6% on Dec 31, 2023 and a high of 29.6% on Sep 30, 2025.

Back to Top